PRESSE RELEASE

AT CES 2019, EVOLUCARE, ASSOCIATED WITH ADCIS, ENTERS INTO AN EXCLUSIVE AND GLOBAL LICENSE AGREEMENT WITH SATT OUEST VALORISATION, A FRENCH TECHNOLOGY TRANSFER OFFICE, AND AP-HP PARIS HOSPITALS

Las Vegas, January 10, 2019

Evolucare, an essential SME in the hospital information system, and ADCIS, another SME and a specialist of image processing and analysis, both proudly announced on Thursday, January 10, the execution of an exclusive worldwide license agreement with SATT Ouest Valorisation and AP-HP at CES (Consumer Electronics Show) 2019 in Las Vegas.

Member of the French HealthTech delegation led by SATT (Technology Transfer Accelerator Offices), the partners seize a unique opportunity to promote internationally a long-term partnership for the automated screening of diabetic retinopathy and in the near future, other eye pathologies. The innovation, called OphtAI, is an Artificial Intelligence that is the outcome of 3 years of collaborative research between researchers, clinicians and industrials. Embedded in the Evolucare tele-ophthalmology and imaging platform, OphtAI will enable better care for nearly half a billion people at risk worldwide.

OphtAI, THE BEST OF ACADEMIC RESEARCH BROUGHT TO MARKET

Revolutionizing the detection of diabetic retinopathy (DR) to cope with the insufficient number of ophthalmologists and growing number of diabetics in the world, this is the objective of the OphtAI solution, put forward at the CES 2019, showcase event for global innovations. The signing of a technology transfer agreement between SATT Ouest Valorisation, AP-HP, Evolucare, and ADCIS for an exclusive exploitation by the industry, seals the transfer of technology and the launch of the solution on the market. The outstanding performance of the algorithm, OphtAI solution's central component that has been developed by the Laboratory of Medical Image Processing (LaTIM), a joint research unit of the University of Western Brittany (UBO) and INSERM (l’Institut National de la Santé Et de la Recherche Médicale), allows a very fine detection of DR. Achieving such an unparalleled level of performance was made possible through close collaboration with AP-HP, which provided LaTIM researchers with their own medical expertise as well as fundus image databases. CES Marking Medical Device is underway and market release, therefore, imminent. A multicentric clinical field trial, launched in the upcoming weeks, will confirm the robustness of the solution.

A JOINT VENTURE WILL LEAD THE MARKET RELEASE

Evolucare, a key player in the digital transformation of healthcare facilities (turnover: € 22 million in 2017, ~ 2000 clients, 230 employees), is also a supplier of the DR screening tele-ophthalmology platform used between 2004 and 2017 for screening of diabetic retinopathy by the AP-HP for, among other things, coordination of care, and activity monitoring. The addition of the OphtAI solution to the platform brings with its automatic sorting algorithm the latest innovations from AI and Deep Learning. It thus enables the global coverage of the DR screening activity. OphtAI’s commercial exploitation will lead to the creation of a Joint Venture (JV) with ADCIS, a company specializing in image processing and historical partner of this collaborative project. This JV aims to develop tools for the detection, diagnosis and monitoring of pathologies detectable by the retina with the help of academic partners who keep on providing their scientific expertise, especially in the field of artificial intelligence. It is part of the future and intends to set up an ambitious export and recruitment plan to support its development.

OphtAI is a breakthrough innovation that will undoubtedly bring a paradigm shift in the organization of ophthalmic care. It is the result of a successful public-private R & D partnership that originated in the RETINOPTIC (*) project. Its success perfectly illustrates the strategic positioning of clinical, research and industrial partners, which is resolutely focused on digital health and precision medicine. It also reinforces Evolucare’s growth ambition through collaborative innovation.

(*) RETINOPTIC, laureate project of Interministerial Unique Fund (FUI 19), supported by Systematic Paris-Region et Mediocenter for excels, aims to the design of a low-cost innovating portable medical device as well as new image processing algorithms hosted in the cloud to enable facing the growing need in massive diabetic retinopathy and age-related macular degeneration screening (MD). This project reunited various partners: ADCIS, AP-HP, Degetel, Effilux, Evolucare, Graduate School ParisTech Optical Institutes, Mines ParisTech, West Brittany University, thanks to financial support of Regional Council of Ile de France, of Bpifrance and of Seine-et-Marne’s department.
ABOUT EVOLUCARE

Evolucare, an essential actor for health information systems for more than 20 years, has been editing and integrating a large array of software dedicated to all healthcare institutions, from health to medico social. It offers an ever-expanding portfolio of products and services in order to satisfy the most needs of its customers (administrative management, electronic medical record, anesthesia, reanimation, pharmacy, operating room and imaging). The group provides almost 2000 health facilities and currently intends in an international market opening strategy. Thanks to its expertise for data management and coordination of care, Evolucare initiated the shift to e-health open-innovation in order to add to its historical offer computer-aided decision software. Evolucare Labs embodies this strategy, which goal is to develop collaborative projects for artificial intelligence expert algorithms-based precision medicine. These disruptive projects follow 4 strategic orientations:

- Computer aided diagnosis
- Computer aided therapeutic strategy
- Computer aided connected patient support and follow-up
- Computer aided coordination and optimization of care

www.evolucare.com

ABOUT ADCIS

Since its inception in 1995, ADCIS (Advanced Concepts in Imaging Software) has been designing, developing and distributing innovative and high-performance image processing and image analysis software products such as the Aphelion™ imaging environment, well reputed throughout and with a worldwide user community, as well as applications in various fields using imaging, including ophthalmology. ADCIS collaborates with numerous international research laboratories in order to integrate the most advanced tools in its software suite and to develop specific applications for all domains. Since 2008, ADCIS has been working on advanced retina and eye anterior segment diagnosis tools using acquisition systems and allowing for accurate detection and analysis for various diseases. Thanks to its United States subsidiary and its specialized distributors network, thousands of users in the world trust the company software tools and develop extremely innovating solutions.

www.adcis.net

ABOUT SATT OUEST VALORISATION

Ouest Valorisation SAS is the private affiliate of 25 academic institutions in the western part of France. Founded in July 2012, the company is responsible for the maturation, licensing and the transfer of technologies of six french major campuses to the commercial sector. Granted in the framework of a national initiative called “SATT” (société d’acceleration du transfert de technologies), Ouest Valorisation SAS protects and manages the intellectual property developed by more than 7000 full time equivalent faculty members, researchers, and technologists from universities, engineering schools hospitals and national research institutions locally present in academic research labs.

http://www.ouest-valorisation.fr/

A PROPOS DE L’AP-HP

AP-HP, Greater Paris University Hospitals, is a first-in-class European and world-renowned university hospital. AP-HP is deeply structured around the 7 Universities of Paris and well integrated in the Paris and Ile-de-France metropolitan area. It collaborates closely with the entire French institutional research ecosystem (CNRS, INSERM, CEA, INRA, Institut Pasteur, etc.) thanks to the presence of joint research units distributed among its 10 hospital clusters. AP-HP also hosts 3 world-class Hospital-University-Institutes. A major player in applied research and health innovation, Greater Paris University Hospitals have created a network of support structures for the organization of research and for clinical investigation with: 14 clinical research units, 17 centers for clinical investigation, 4 centers for clinical research and 2 centers for early stage trials, 12 platforms for biological sample collections, 2 sites of state-of-the-art research on cancer, and 1 health data warehouse collecting healthcare data from the 8 million patients admitted each year. AP-HP researchers annually sign nearly 10,000 scientific publications and more than 4,450 research projects are currently under development, with academic or industrial promotion, at the national, European and international levels. With a portfolio of more than 500 patents, databases and unique biological materials, AP-HP promotes outstanding research by biologists and clinical researchers in its 39 hospitals. Nearly half of the patented innovations are licensed to companies around the world and leaded to the creation of about 60 startups.

http://www.aphp.fr
CONTACTS

EVOLUCARE
Fatima-Zohra HENICHE
fz.heniche@evolucare.com;
06 68 52 53 45

SATT OUEST VALORISATION
Bruno WESTEEL
bruno.westeel@ouest-valorisation.fr
06 18 70 31 91

ADCIS
Gervais GAUTHIER
gervais.gauthier@adcis.net
02 31 06 23 00

AP-HP
Marine LEROY
service.presse@aphp.fr
01 40 27 37 22